Telix applauds NCCN radiotracer update

Injection kit developer Telix applauded the National Comprehensive Cancer Network's (NCCN) decision to update its guidelines on prostate-specific membrane antigen (PSMA) PET imaging in prostate cancer testing.

The NCCN added gallium-68 (Ga-68) PSMA-11 and F-18 piflufolastat (Pylarify, Lantheus Medical Imaging) to recommendations on the use of radiotracers in prostate cancer testing.

Telix's New Drug Application for investigational imaging product Illuccix, a kit for the preparation of Ga-68 PSMA-11, is in the late stages of review by the U.S. Food and Drug Administration, the company said.

The NCCN update suggests conventional imaging with CT or MRI is not a necessary prerequisite to PSMA-PET and that PSMA-PET/CT or PSMA-PET/MRI can serve as equally effective imaging tools for patients with suspected prostate cancer, Telix said.

NCCN guidelines are a recognized standard for clinical direction and policy in cancer care and are used widely by clinicians and payors.